RE:RE:RE:RE:Whats this?I added about 4% to my position today at 3,50 usd....My last purchase before today was at 2.80 cad at the end of January (based on valuation) for about 5 % addition ...However the peer reviewed article is the first unbiased validation imo and that was the basis of my purchase .....Moreover the share price does not include anything for the oncology platform so even if it fails the SP should not be punished imo,,,,
qwerty22 wrote: It lays out all the preclinical breast cancer data in a little more detail than we've seen before. It's really nice to get this preclinical peer reviewed paper this early, often they come out later in the process. I read it once, nothing jumped out as surprising (+ or -). Can't remember if they've shown the Kaplan-Meier plots before, they are interesting, look strong. I'll read it again and see what jumps out.
What looks solid is
How the drug enters the cell
How docetaxel is toxic after it's released in the cell
The simplicity of the molecule
It's stability in the blood
palinc2000 wrote: Is it fair to say that this gives a little more credence to the story?